ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos761 M703 M718 M708 M761 M2.89 BInvestigación y desarrollo211 M140 M134 M118 M126 M518 MBeneficio operativo-435 M58 M191 M172 M-729 M-308 MTotal de ingresos no operativos3 M5 M-13 M6 M31 M29 MGastos por intereses, netos de intereses capitalizados113 M81 M-14 M-10 M113 M—Ingresos no operativos, una vez deducidos los gastos por intereses-114 M-79 M1 M9 M-113 M-182 MIngresos/gastos extraordinarios4 M3 M07 M31 M41 MBeneficio antes de impuestos-521 M-3 M133 M121 M-756 M-505 MParticipación en los beneficios——————Impuestos-33 M-67 M11 M172 M279 M395 MParticipación minoritaria2 M00000Otros ingresos/gastos después de impuestos-21 M-6 M-14 M-2 M-8 M-30 MBeneficio neto antes de actividades interrumpidas-490 M64 M122 M-51 M-1.03 B-900 MOperaciones suspendidas-22 M62 M-31 M5 M-93 M-57 MBeneficio neto-512 M126 M91 M-46 M-1.13 B-957 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-512 M126 M91 M-46 M-1.13 B-957 MBeneficio básico por acción-10.250.18-0.09-2.21-1.87Beneficio por acción diluido-10.250.18-0.09-2.21-1.87Número medio de acciones ordinarias510 M512 M513 M514 M513 M2.05 BAcciones diluidas510 M514 M514 M514 M513 M2.06 BEBITDA-953 M69 M227 M180 M-1.61 B-1.14 BEBIT-1.2 B-178 M-30 M-57 M-1.85 B-2.12 BCosto de los ingresos1.79 B1.76 B1.82 B1.89 B2.4 B7.87 BOtros costes de producción——————Amortización y depreciación (flujo de caja)245 M247 M257 M237 M240 M981 M
Baxter International Inc
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals.
Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients.
Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services".
Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology.